Donm Bailey News Today

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A Information ...

HC Wainwright reiterated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a research report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock. Separately, Cantor Fitzgerald reissued an overweight rating and set a $6.00 price target on shares of Lineage Cell […]

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $7.00 price objective on the stock. Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $6.00 price target on shares of […]

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Free Report) Director Don M. Bailey acquired 96,155 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was purchased at an average price of $1.04 per share, with a total value of $100,001.20. Following the transaction, the director now owns 158,801 shares […]

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into a definitive agreement with certain investors for the purchase and sale of...

CARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into a definitive agreement with certain investors fo...